Stoic Venture Capital grows health portfolio

STOIC Venture Capital has announced it has concentrated the bulk of its portfolio toward healthcare after significantly increasing its holdings to 17 companies since establishing two and a half years ago.

Stoic Venture Capital is the co-investment Fund of Uniseed, a commercialisation fund which focuses on financing early-stage companies that emerge from member universities.

Stoic Venture Capital partner, Geoff Waring said nine of the total 17 companies were developing new drugs, medical devices and treatments. The fund recently added Ferronova to its portfolio.

“Many investors prefer software to more medical and science-based technology because of the belief lengthy regulatory approval processes, clinical trials and quality-certified manufacturing processes means a longer holding period,” Dr Waring said.

“But in doing so, they do not consider that health venture capital investors typically sell to pharmaceutical companies at the end of phase 2 trials, while software companies must wait  to sell only after the product is long in the market with significant revenues.”

Dr Waring said Stoic Venture Capital’s close partnership with university-focused investment fund Uniseed gave investors access to some of the richest opportunities from Australia’s top universities that have the potential to improve the lives of millions of people.

“These companies are bringing new solutions to billion-dollar global health challenges, from enhancing immunity to treat respiratory diseases (Ena Therapeutics), to addiction rehabilitation (Kinoxis) and hot flushes in women receiving breast cancer treatment (Que Oncology),” Dr Waring said.

“Many are at an early stage of clinical development, but we believe they are the next generation of world leading medical and scientific companies.”

Dr Waring said Stoic Venture Capital’s portfolio not only had potential to deliver investors high returns but had a double purpose of contributing to the growth of Australian medical and scientific innovation.

“We recognise Australia’s need for stronger capabilities in health care to meet the needs of our ageing population,” Dr Waring said.

“Investing in health and science today, plays a vital role in creating a whole new generation of jobs and innovation for the future.

“We are committed to supporting early-stage health and science companies through initial trials to development and manufacturing.”

 

About Stoic Venture Capital

Stoic Venture Capital provides financing for early-stage companies, particularly those arising from university research. Stoic is unconditionally registered as an Early Stage Venture Capital Limited Partnership (ESVCLP) and takes a collaborative approach to investing in the highest potential companies.  www.stoicvc.com.au

About Uniseed

Uniseed is Australia’s longest running early stage commercialisation fund that makes investments in research emanating from five of Australia’s leading research organisations – The University of Queensland, The University of Sydney, The University of New South Wales, The University of Melbourne and the CSIRO. Uniseed is a mutual fund, owned by research organisations, for research organisations. The fund facilitates the commercialisation of its research partners’ most promising intellectual property and secures targeted investment in resulting products and technologies. Uniseed has supported 57 start-up companies to date, being the seed investor in most of these. www.uniseed.com

ends